NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Annual report FY2026 BAFNA PHARMACEUTICALS LIMITED Annual Report FY 2025-26 Summary for Retail Investors --- HEADLINE NUMBERS • Revenue from Operations: ₹1,506.17 milli | 2026-08-19 |
| Quarterly results · Q1 FY27 BAFNA PHARMACEUTICALS LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Q1 FY2026-27 Revenue from Operations: INR 2,658.32 Lakhs (down 23.3% YoY fro | 2026-08-11 |
| Quarterly results · Q4 FY26 BAFNA PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Year ended March 31, 2026 revenue from operations: INR 15,061.74 lakhs (vs INR | 2026-05-29 |
| Quarterly results · Q3 FY26 BAFNA PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations (9-month period ended Dec 31, 2025): INR 10,837.80 lakh | 2026-02-11 |
| Quarterly results · Q2 FY26 BAFNA PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY H1 FY2025-26 (April-September 2025) --- HEADLINE NUMBERS • Total Income H1: INR 7,186.75 Lakhs (H | 2025-11-11 |
| Annual report FY2025 BAFNA PHARMACEUTICALS LIMITED – SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Operating Revenue FY25: ₹145.86 Cr (marginal decline from ₹152. | 2025-08-26 |
| Quarterly results · Q1 FY26 BAFNA PHARMACEUTICALS LIMITED – Q1 FY2026 SUMMARY HEADLINE NUMBERS • Revenue from Operations (Q1 FY2026): ₹3,462.40 lakhs (vs ₹3,328.63 lakhs in Q1 | 2025-08-12 |
| Quarterly results | 2025-02-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bafna Pharmaceuticals Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.